Roche Holding AG (SWX:RO)
276.80
-1.80 (-0.65%)
Jun 18, 2025, 2:38 PM CET
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
604.32K CHF
Profits / Employee
80.17K CHF
Market Cap
209.89B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 103,249 | -356 | -0.34% |
Dec 31, 2023 | 103,605 | -8 | -0.01% |
Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
Dec 31, 2021 | 100,920 | -545 | -0.54% |
Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
Roche Holding AG | 103,249 |
Novartis AG | 75,883 |
Lonza Group AG | 18,944 |
Alcon | 25,599 |
Galderma Group AG | 6,545 |
Sandoz Group AG | 22,049 |
Straumann Holding AG | 11,815 |
Sonova Holding AG | 18,366 |
Roche Holding AG News
- 23 hours ago - Roche And Prothena: Why Moving On Makes Sense - Seeking Alpha
- 1 day ago - Roche: Despite Venclexta Study Failure, PD Program Is Another Growth Avenue - Seeking Alpha
- 1 day ago - Genentech Provides Update on Phase III Verona Study - Business Wire
- 2 days ago - Prothena jumps as partner Roche to advance Parkinson's drug into late-stage studies - Seeking Alpha
- 2 days ago - Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures - WSJ
- 2 days ago - Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson's Disease - Benzinga
- 2 days ago - Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson's Disease - Business Wire
- 2 days ago - Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease - Benzinga